Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.80-0.03 (-1.06%)

Delayed quote: Oct 6, 2026, 3:38 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:42:10.557Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:42:10.557Z.

Quote observation: 2026-10-06T19:38:49.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 61,117,078
Total debt · period ending 2026-06-30: 1,400,000
Cash · period ending 2026-06-30: 43,173,000
TTM operating EBITDA · period ending 2026-06-30: -47,731,000

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KLRS EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KLRS Competitors' EV/EBITDA Ratio

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$61.12M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$60.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs KLRS

Market Cap

$61.99M

EV/EBITDA Ratio

N/A

TTM Avg

250.18x

3Y Avg

250.18x

5Y Avg

250.18x

GUTS

Fractyl Health, Inc.

vs KLRS

Market Cap

$60.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RNXT

RenovoRx, Inc.

vs KLRS

Market Cap

$62.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$59.03M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs KLRS

Market Cap

$63.02M

EV/EBITDA Ratio

N/A

TTM Avg

7.83x

3Y Avg

18.88x

5Y Avg

17.80x

INKT

MiNK Therapeutics, Inc.

vs KLRS

Market Cap

$58.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs KLRS

Market Cap

$58.85M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs KLRS

Market Cap

$63.47M

EV/EBITDA Ratio

N/A

TTM Avg

29.74x

3Y Avg

29.74x

5Y Avg

29.74x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$61.12M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.04M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$61.99M	N/A	250.18x	250.18x	250.18x
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A
RenovoRx, Inc. (RNXT)vs ›	$62.17M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$59.03M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	7.83x	18.88x	17.80x
MiNK Therapeutics, Inc. (INKT)vs ›	$58.54M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$58.85M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.47M	N/A	29.74x	29.74x	29.74x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics